Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma

Published:2019-01 Issue:1 Volume:42 Page:42-45
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Prisciandaro Michele,Ratta Raffaele,Massari Francesco,Fornarini Giuseppe,Caponnetto Salvatore,Iacovelli Roberto,De Giorgi Ugo,Facchini Gaetano,Scagliarini Sarah,Sabbatini Roberto,Caserta Claudia,Peverelli Giorgia,Mennitto Alessia,Verzoni Elena,Procopio Giuseppe

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference23 articles.

1. Renal cancer;Capitanio;The Lancet,2016

2. The 2016 WHO Classification of Tumours of the Urinary System and male genital organs-part A: renal, penile, and testicular tumours;Moch;Eur Urol,2016

3. Management of renal collecting duct carcinoma: a systematic review and the McMaster experience;Dason;Curr Oncol,2013

4. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma;Harshman;Cancer J,2013

5. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET;Rankin;Proc Natl Acad Sci U S A,2014

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A fatal case of cabozantinib-induced cardiomyopathy;Future Cardiology;2024-08-05

2. Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients—Real-World Experience in a Single-Center Retrospective Study and Narrative Review;Medicina;2024-02-26

3. SEOM SOGUG clinical guideline for treatment of kidney cancer (2022);Clinical and Translational Oncology;2023-08-09

4. MET Inhibitors for Papillary Renal Cell Carcinoma;Kidney Cancer;2023-07-20

5. Endocrine-related adverse conditions induced by tyrosine kinase inhibitors;Annales d'Endocrinologie;2023-05